Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

In the results, dual GLP-1/GIP agonist Zepbound (tirzepatide) outperformed GLP-1 agonist Wegovy (semaglutide) on all weight-loss endpoints at 72 weeks among patients with obesity or who were ...

People taking Zepbound lost more body weight. Those on Zepbound lost 20.2% of their body weight (about 50 pounds on average), while participants on Wegovy lost 13.7% (about 33 pounds).